CA 19.9在可切除胰腺癌管理中的作用：现状与未来展望
Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives.
作者信息
Coppola Alessandro, La Vaccara Vincenzo, Farolfi Tommaso, Fiore Michele, Cammarata Roberto, Ramella Sara, Coppola Roberto, Caputo Damiano
机构信息
General Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
General Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
出版信息
Biomedicines. 2022 Aug 26;10(9):2091. doi: 10.3390/biomedicines10092091.
BACKGROUND
Surgery still represents the gold standard of treatment for resectable pancreatic ductal adenocarcinoma (PDAC). Neoadjuvant treatments (NAT), currently proposed for borderline and locally advanced PDACs, are gaining momentum even in resectable tumors due to the recent interesting concept of "biological resectability". In this scenario, CA 19.9 is having increasing importance in preoperative staging and in the choice of therapeutic strategies. We aimed to assess the state of the art and to highlight the future perspectives of CA 19.9 use in the management of patients with resectable pancreatic cancer.
METHODS
A PubMed database search of articles published up to December 2021 has been carried out.
RESULTS
Elevated pre-operative levels of CA 19.9 have been associated with reduced overall survival, nodal involvement, and margin status positivity after surgery. These abilities of CA 19.9 increase when combined with radiological or different biological criteria. Unfortunately, due to strong limitations of previously published articles, CA 19.9 alone cannot be yet considered as a key player in resectable pancreatic cancer patient management.
CONCLUSION
The potential of CA 19.9 must be fully explored in order to standardize its role in the "biological staging" of patients with resectable pancreatic cancer.
背景
手术仍然是可切除胰腺导管腺癌（PDAC）治疗的金标准。新辅助治疗（NAT）目前被推荐用于临界可切除和局部进展期PDAC，由于最近“生物学可切除性”这一有趣概念，其在可切除肿瘤中的应用也越来越多。在这种情况下，CA 19.9在术前分期和治疗策略选择中的重要性日益增加。我们旨在评估CA 19.9在可切除胰腺癌患者管理中的应用现状，并突出其未来前景。
方法
对截至2021年12月发表的文章进行了PubMed数据库检索。
结果
术前CA 19.9水平升高与总体生存率降低、淋巴结受累及术后切缘状态阳性相关。当与放射学或不同生物学标准结合时，CA 19.9的这些作用会增强。不幸的是，由于先前发表文章的严重局限性，CA 19.9目前还不能被视为可切除胰腺癌患者管理的关键指标。
结论
必须充分探索CA 19.9的潜力，以规范其在可切除胰腺癌患者“生物学分期”中的作用。
Zotero 插件